[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647547":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":25,"locations":31,"responsibleParty":49,"collaborators":11,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":11,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":11,"enrollmentInfo":60,"targetDuration":11,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":11,"overallStatus":69,"whyStopped":11,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Fujian Shengdi Pharmaceutical Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Ribupatide Injection","EXPERIMENTAL",null,[13],"Drug: Ribupatide Injection",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,23],{"type":21,"name":9,"description":9,"armGroupLabels":22,"otherNames":11},"DRUG",[9],{"type":21,"name":15,"description":15,"armGroupLabels":24,"otherNames":11},[15],[26],{"name":27,"role":28,"phone":29,"phoneExt":11,"email":30},"Yiming Li","CONTACT","+0518-82342973","yiming.li@hengrui.com",[32],{"facility":33,"status":11,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Shanghai Sixth People's Hospital","Shanghai","Shanghai Municipality","200233","China","CN",{"type":40,"coordinates":41},"Point",[42,43],121.45806,31.22222,{"lat":43,"lon":42},[46],{"name":47,"role":48,"phone":11,"phoneExt":11,"email":11},"Changqing Zhang","PRINCIPAL_INVESTIGATOR",{"type":50,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100647547","phase-3-a-trial-of-ribupatide-injection-in-participants-with-obesity-and-knee-osteoarthritis-100647547",false,"NCT07709910","A Trial of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis","A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis","Inclusion Criteria:\n\n\\-\n\n1、Voluntarily sign the informed consent form, agree to comply with the protocol requirements, and be willing and able to complete the study;\n\n1. 2、Aged ≥18 years on the date of signing the informed consent form, male or female;\n2. 3、BMI ≥28.0 kg\u002Fm² at screening;\n3. 4、Self-reported dietary and exercise control for 3 months or more prior to screening, and body weight change (difference between maximum and minimum body weight within 3 months) ≤5.0 kg in the 3 months prior to screening;\n4. 5、Based on the American College of Rheumatology criteria, the clinical diagnosis is knee osteoarthritis, and the target knee joint X-ray examination shows a K-L grade of 2-3 at screening.\n\nExclusion Criteria:\n\n1. Existence of endocrine diseases that may significantly affect body weight;\n2. Existence of any conditions affecting gastric emptying;\n3. Known history of acute or chronic pancreatitis, pancreatic injury, acute cholecystitis, or symptomatic\u002Ftreated gallbladder diseases;\n4. Known history or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2);\n5. Severe infection, major trauma, or major\u002Fmedium surgery within 1 month prior to screening;\n6. History of severe cardiovascular or cerebrovascular diseases within 6 months prior to screening;\n7. History of malignancy in any organ system within 5 years prior to screening;\n8. Existence or suspicion of depression, bipolar disorder, suicidal tendencies, schizophrenia, or other serious mental illnesses;\n9. Known or suspected history of alcohol and\u002For drug abuse or addiction;\n10. Symptoms or signs of acute or chronic hepatitis, or any liver disease other than metabolic dysfunction-associated fatty liver disease;\n11. Existence of serious hematologic diseases or any conditions causing hemolysis or red blood cell instability;\n12. Existence of autoimmune diseases requiring systemic glucocorticoid or immunosuppressive therapy during the study period;\n13. Known or suspected allergy to GLP-1 and\u002For GIP receptor agonists or their excipients;\n14. Participation in any drug or medical device clinical trial within 3 months prior to screening;\n15. Blood donation or cumulative blood loss ≥400 mL within 3 months prior to screening, or receipt of blood transfusion within 3 months;\n16. Participants with mental incompetence or language impairments that prevent full understanding or participation in the trial process.","ALL","18 Years",{"count":61,"type":62},382,"ESTIMATED","INTERVENTIONAL",[65],"PHASE3","The study is being conducted to evaluate the efficacy and safety of Ribupatide Injection in participants with obesity and knee osteoarthritis, and to explore its improvement on knee joint structure.",[68],"Participants With Obesity and Knee Osteoarthritis","NOT_YET_RECRUITING","2026-07-16",{"date":72,"type":73},"2026-07-17","ACTUAL",{"date":75,"type":62},"2026-07",{"date":77,"type":62},"2028-12",{"name":5,"class":6},1]